Emerging evidence supports direct-acting antiviral therapy for HCC patients beyond the early stage |
Teng-Yu Lee1,2, Pei-Chien Tsai3, Shou-Wu Lee1,2,4, Ming- Lung Yu3,5 |
1Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan 2School of Medicine, Chung Shan Medical University, Taichung, Taiwan 3Hepatobiliary Division, Department of Internal Medicine and Hepatitis Center, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan 4Department of Post-Baccalaureate Medicine, College of Medicine, Chung Hsing University, Taichung, Taiwan 5Hepatitis Research Center, College of Medicine and Center for Liquid Biopsy and Cohort Research, Kaohsiung Medical University, Kaohsiung, Taiwan |
|
Received: February 28, 2025 Accepted: March 1, 2025 |
|
KeyWords:
chronic hepatitis C; antivirals; sustained virological response; liver cancer; survival |
|
|